Myriad Genetics, Inc.

MYGNNASDAQHealthcare● Active

$4.40

$-0.18(-3.83%)

Market Cap$415099839

P/E Ratio—

52W High$8.59

52W Low$3.53

Avg Volume1.9M

Open$4.59

Beta1.64

Forecast Market Cap PE Ratio

Myriad Genetics, Inc.（MYGN）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

mygn · 股价预测 · 36 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 36 位华尔街分析师

Hold

36 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 36 · 买入占比: 22.2%

12 个月目标价

High

$6.00

Consensus

$6.00

+36.4% upside

Low

$6.00

Median: $6 · Last Close: $4.40

Myriad Genetics, Inc.（MYGN）的分析师共识为 Hold，基于过去 3 个月内 36 位华尔街分析师的评级。MYGN 的 12 个月平均目标价为 $6.00，相对当前价 $4.40 代表 +36.4% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$4.62	↑ 5.00%	$4.58	$4.66

1-day model range: $4.58–$4.66. Peak: $4.66 (+5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$2	$2	$2	-50.0%
2028	$1	$2	$2	-63.8%
2029	$1	$1	$1	-69.2%
2030	$1	$1	$1	-71.8%
2031	$1	—	$1	-73.1%

Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

36%7%57%

5Buy

1Neutral

8Sell

RSI (14)67.0Neutral

MACDBULLISH

Refreshes daily from EOD close

Moving Averages · MYGN · Jun 8, 2026

Simple Moving Average (SMA)

MA 5$4.47SELL

MA 10$4.26BUY

MA 20$4.03BUY

MA 50$4.44SELL

MA 100$4.75SELL

MA 200$5.93SELL

Current $MYGN · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$4.43SELL

EMA 10$4.31BUY

EMA 20$4.24BUY

EMA 50$4.42SELL

EMA 100$4.85SELL

EMA 200$5.88SELL

Current $MYGN · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2026-05-06	TD Cowen	Maintains	Hold→Hold
2026-05-06	Wells Fargo	Maintains	Equal Weight→Equal Weight
2026-02-24	UBS	Maintains	Neutral→Neutral
2026-02-24	Wells Fargo	Maintains	Equal Weight→Equal Weight
2025-11-11	Piper Sandler	Maintains	Overweight→Overweight
2025-11-05	Wells Fargo	Maintains	Equal Weight→Equal Weight
2025-11-04	UBS	Maintains	Neutral→Neutral
2025-11-04	TD Cowen	Maintains	Hold→Hold
2025-05-21	Scotiabank	Downgrade ↓	Sector Outperform→Sector Perform
2025-05-15	Piper Sandler	Maintains	Overweight→Overweight

TD Cowen2026-05-06

Maintains

Hold→Hold

Wells Fargo2026-05-06

Maintains

Equal Weight→Equal Weight

UBS2026-02-24

Maintains

Neutral→Neutral

Wells Fargo2026-02-24

Maintains

Equal Weight→Equal Weight

Piper Sandler2025-11-11

Maintains

Overweight→Overweight

Wells Fargo2025-11-05

Maintains

Equal Weight→Equal Weight

UBS2025-11-04

Maintains

Neutral→Neutral

TD Cowen2025-11-04

Maintains

Hold→Hold

Scotiabank2025-05-21

Downgrade ↓

Sector Outperform→Sector Perform

Piper Sandler2025-05-15

Maintains

Overweight→Overweight

Wall Street analysts have recently issued updated ratings on Myriad Genetics, Inc. (MYGN) stock. Of the recent 175 rating actions, 28 were upgrades and 36 were downgrades. 36 analysts currently cover MYGN.

分析师推荐趋势

Buy ratings1 → 0↓ 1

Hold ratings1 → 2↑ +1

Sell ratings1 → 0↓ 1

MYGN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$864M

↓ 11.0% YoY

Revenue Next Year

$916M

↑ 6.0% YoY

EPS This Year

$0.06

EPS Next Year

$0.15

↑ 146.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MYGN EPS of $0.06 for the current fiscal year, based on estimates from 5 analysts. The MYGN revenue forecast is $864M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

MYGN 股价预测由两类独立数据源支撑：来自 36 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。MYGN 的共识目标价为 $6.00（+36.4% 上行空间），分析师共识为 Hold。

MYGN 的短期预测（明日）为 $4.62（+5.00%）。 MYGN 对 2027 年的股价预测均值为 $2。 MYGN 对 2030 年的预测区间为 $1–$1。

Myriad Genetics, Inc. 在 NASDAQ 上市，代码 MYGN。MYGN 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 22% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

MYGN 预测 · 8 个问题

根据 36 位华尔街分析师，MYGN 的 12 个月平均目标价为 $6.00，最高 $6.00、最低 $6.00。若有图表，中位目标价可在上方查看。相对当前价 $4.40，隐含约 +36.4% 的上行空间。

MYGN 目标价MYGN 分析师目标价MYGN 12个月目标价目标价 MYGN

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.